ABEO
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
46.55M
GET INTRADAY SIGNALS
ABEO Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
45 days until earnings call
+Compare
ABEO
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
46.55M

ABEO Price Prediction, Abeona Therapeutics AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
ABEO Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Mar 27, 2023

ABEO's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ABEO turned positive on March 27, 2023. Looking at past instances where ABEO's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where ABEO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on March 24, 2023. You may want to consider a long position or call options on ABEO as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ABEO moved above its 50-day moving average on March 24, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ABEO advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ABEO moved out of overbought territory on March 09, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The 10-day moving average for ABEO crossed bearishly below the 50-day moving average on March 22, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABEO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ABEO broke above its upper Bollinger Band on March 03, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ABEO entered a downward trend on March 06, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.031) is normal, around the industry mean (21.930). P/E Ratio (0.113) is within average values for comparable stocks, (123.806). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.812). Dividend Yield (0.000) settles around the average of (0.028) among similar stocks. P/S Ratio (3.477) is also within normal values, averaging (302.440).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I. Advisor
published Earnings

ABEO is expected to report earnings to fall 49.32% to -75 cents per share on March 27

Abeona Therapeutics ABEO Stock Earnings Reports
Q4'22
Est.
$-0.75
Q3'22
Missed
by $0.01
Q2'22
Missed
by $0.20
Q1'22
Missed
by $3.40
Q4'21
Missed
by $0.30
The last earnings report on November 14 showed earnings per share of -148 cents, missing the estimate of -147 cents. With 73.81K shares outstanding, the current market capitalization sits at 46.55M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.98B. The market cap for tickers in the group ranges from 160 to 340.76B. NONOF holds the highest valuation in this group at 340.76B. The lowest valued company is CDXI at 160.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -1%. ZURA experienced the highest price growth at 106%, while PHYOF experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 12%. For the same stocks of the Industry, the average monthly volume growth was -14% and the average quarterly volume growth was -67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 61
SMR Rating: 92
Profit Risk Rating: 95
Seasonality Score: -3 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Generic
Address
1330 Avenue of the Americas
Phone
+1 646 813-4701
Employees
90
Web
http://www.abeonatherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HNRG8.810.58
+7.05%
Hallador Energy Company
GDEN42.110.59
+1.42%
Golden Entertainment
CVU3.650.01
+0.27%
CPI Aerostructures
MPW7.46-0.07
-0.93%
Medical Properties Trust
MU59.79-1.37
-2.24%
Micron Technology

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with ABCL. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+0.37%
ABCL - ABEO
36%
Loosely correlated
+3.27%
ATAI - ABEO
34%
Loosely correlated
+9.60%
CRBU - ABEO
32%
Poorly correlated
+1.30%
RXDX - ABEO
32%
Poorly correlated
+2.81%
FBIO - ABEO
32%
Poorly correlated
-0.58%
More